- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 125
Venafi picks first three developers for fund
Jetstack, OpenCredo and Cygnacom are the first three recipients of cash from the cybersecurity technology producer's Machine Identity Protection Development Fund.
Dec 17, 2018XianLife eats up corporate funding
Convenience store management software provider XianLife has raised an eight-figure sum from investors including Megvii and SBI Investment.
Dec 17, 2018MedaPhor clues on to Parkwalk investment
Parkwalk Advisors has invested an undisclosed sum in Cardiff ultrasound simulation technology developer MedaPhor through its Opportunities Fund.
Dec 17, 2018Xorlab gets the message in $1.9m round
ETH Zurich-founded cybersecurity business Xorlab focuses on thwarting email attacks through a combination of machine learning and advanced dynamic analysis.
Dec 17, 2018Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Dec 17, 2018Corporate venturing deal net: 10-14 December 2018
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Dec 14, 2018DenovoMatrix binds funding
TU Dresden spinout DenovoMatrix hopes to commercialise a method for effectively cultivating stem cell production.
Dec 14, 2018Sensorygen bites into $50,000
Vertical Venture Partners has joined university venture fund Highlander Venture Fund as an investor in UC Riverside-founded mosquito repellent developer Sensorygen.
Dec 14, 2018Zest Tea brews $1m
The tea product supplier has become the fourth business backed by University of Maryland Momentum Fund.
Dec 13, 2018Istesso stakes $7.6m
IP Group has poured more funding into Istesso, whose treatment for rheumatoid arthritis traces its roots to an Aberdeen spinout, to drive immuno-metabolism therapies for autoimmune diseases.
Dec 13, 2018About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


